Jyothis Thomas George

Jyothis Thomas George

Novo Nordisk A S - Bagsvaerd / Denmark
Medical and Health Sciences / Endocrinology and Metabolism
AD Scientific Index ID: 4432105
person_outline Jyothis Thomas George's MOST POPULAR ARTICLES
1-) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trialJ Rosenstock, V Perkovic, OE Johansen, ME Cooper, SE Kahn, N Marx, ...Jama 321 (1), 69-79, 20198462019
2-) How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trialSE Inzucchi, B Zinman, D Fitchett, C Wanner, E Ferrannini, ...Diabetes care 41 (2), 356-363, 20185392018
3-) Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney diseaseC Wanner, JM Lachin, SE Inzucchi, D Fitchett, M Mattheus, J George, ...Circulation 137 (2), 119-129, 2018495*2018
4-) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trialJ Rosenstock, SE Kahn, OE Johansen, B Zinman, MA Espeland, ...Jama 322 (12), 1155-1166, 20196392019
5-) The kisspeptin-GnRH pathway in human reproductive health and diseaseK Skorupskaite, JT George, RA AndersonHuman reproduction update 20 (4), 485-500, 20145382014